EyeGene Inc

EyeGene Inc exhibits a highly leveraged capital structure with a debt-to-equity ratio of 0.04, indicating minimal reliance on debt financing. The company maintains a strong liquidity position with a current ratio of 4.76, supported by cash and equivalents of 2,761,372,760 KRW. However, the company's operating cash flow is negative at -5,981,051,440 KRW, and free cash flow is significantly negative at -18,222,571,810 KRW, suggesting ongoing operational cash outflows. Profitability metrics are sharply negative, with a return on equity of -27.49% and a return on assets of -23.08%, both well below the typical performance of the biotechnology industry. The company reported a net loss of 15,706,096,870 KRW and an operating loss of 11,949,415,920 KRW, indicating a lack of current earnings and operational efficiency. Geographically and segment-wise, EyeGene's revenue concentration is not disclosed in the input data, but the company operates in a single business segment focused on pharmaceuticals. This lack of diversification may increase exposure to sector-specific risks. The company's growth trajectory is unclear, as the most recent actual revenue of 3,363,420,000 KRW is lower than the reported revenue of 3,566,784,890 KRW, suggesting potential volatility or reporting inconsistencies. No forward-looking revenue growth estimates are provided in the input data, limiting visibility into future performance. Risk factors include a low liquidity risk rating and no immediate dilution pressures, as no filing-based flags were detected. However, the company's negative operating and free cash flows suggest potential liquidity challenges in the medium term. No dilution sources were identified in the input data, and the dilution near-term probability is assessed as low. Recent events include the latest financial reporting, which shows a significant net loss and negative cash flows. No recent filings, transcripts, or material events are disclosed in the input data that would suggest a change in strategic direction or operational performance.